Clinical Trial Update: Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)

View source ↗

Summary

Clinical trial update for OTIVACTO (tiotropium/olodaterol) in COPD assessing physical functioning and handling; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiolto Respimat (tiotropium/olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Status: TERMINATED | Results posted: 2019-04-16